$145.93
0.85% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US7599161095
Symbol
RGEN

Repligen Corporation Stock price

$145.93
-0.10 0.07% 1M
-38.82 21.01% 6M
-33.87 18.84% YTD
-15.07 9.36% 1Y
-161.44 52.52% 3Y
+69.28 90.38% 5Y
+125.83 626.02% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-1.25 0.85%
ISIN
US7599161095
Symbol
RGEN
Sector
Industry

Key metrics

Market capitalization $8.24b
Enterprise Value $8.18b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 68.56
EV/Sales (TTM) EV/Sales 13.57
P/S ratio (TTM) P/S ratio 13.68
P/B ratio (TTM) P/B ratio 4.14
Revenue growth (TTM) Revenue growth -17.41%
Revenue (TTM) Revenue $602.35m
EBIT (operating result TTM) EBIT $15.12m
Free Cash Flow (TTM) Free Cash Flow $119.26m
Cash position $809.15m
EPS (TTM) EPS $-0.04
P/E forward 420.51
P/S forward 13.14
EV/Sales forward 13.03
Short interest 8.45%
Show more

Is Repligen Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Repligen Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Repligen Corporation forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Repligen Corporation forecast:

Buy
80%
Hold
20%

Financial data from Repligen Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
602 602
17% 17%
100%
- Direct Costs 348 348
5% 5%
58%
254 254
30% 30%
42%
- Selling and Administrative Expenses 126 126
17% 17%
21%
- Research and Development Expense 42 42
2% 2%
7%
86 86
60% 60%
14%
- Depreciation and Amortization 70 70
21% 21%
12%
EBIT (Operating Income) EBIT 15 15
90% 90%
3%
Net Profit -1.90 -1.90
101% 101%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Repligen Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repligen Corporation Stock News

Neutral
GlobeNewsWire
4 days ago
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters.
Neutral
GlobeNewsWire
about one month ago
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, Septem...
Positive
Reuters
about one month ago
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday.
More Repligen Corporation News

Company Profile

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Head office United States
CEO Olivier Loeillot
Employees 1,783
Founded 1981
Website www.repligen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today